BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025)
BioNTech SE (BNTX) posted Income from Continuing Operations of 174373718.5 for Q4 2025, down 290.98% sequentially from 91303202.63 in Q3 2025, and down 147.59% YoY from 366421362.72 in Q4 2024.
BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025) Analysis & Trends
BioNTech SE has reported Income from Continuing Operations for 8 years, with the latest figure at 174373718.5 in Q4 2025.
- Quarterly Income from Continuing Operations fell 147.59% year-over-year to 174373718.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1056780341.98 (down 41.52% YoY) and the FY2025 annual result came in at 1283578492.83, down 80.55% from the prior year.
- Income from Continuing Operations slipped to 174373718.5 in Q4 2025 per BNTX's latest filing, from 91303202.63 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7221719704.56 in Q3 2021 and troughed at 865602233.83 in Q2 2024.
- A 5-year average of 2030780924.39 and a median of 650437586.83 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2025: Income from Continuing Operations surged 13561718996.32% in 2021, then sank 147.59% in 2025.
- Over 5 years, Income from Continuing Operations stood at 7163088507.63 in 2021, then slumped by 42.08% to 4148835910.98 in 2022, then tumbled by 77.48% to 934453810.95 in 2023, then plunged by 60.79% to 366421362.72 in 2024, then tumbled by 147.59% to 174373718.5 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 174373718.5, 91303202.63, and 474064717.33 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -174.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 366.42 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 7.16 Bn |
| Sep 30, 2021 | 7.22 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 2.60 Bn |